drugset
drugset / Trial / NCT07127289

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

NCT07127289 ↗

Phase 2 Recruiting 20 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, single-center clinical study designed to evaluate the safety of autologous hematopoietic stem cell infusion for the treatment of prolonged cytopenia following CAR-T cell therapy. Approximately 20 patients will be enrolled.

Timeline

Start
2025-08
Primary completion
2027-08
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous hematopoietic stem cell infusion Cell therapy 500000 cells/kg —
Subject Autologous hematopoietic stem cell infusion Cell therapy 3e+06 cells/kg —

Indications

No indication recorded.